[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

[PDF][PDF] PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016

M Banach, P Jankowski, J Jóźwiak… - Archives of Medical …, 2017 - termedia.pl
Guidelines The Guidelines have been officially approved and supported by the Polish
Society of Family Medicine (PSFM). With the consent of Authors and Editorial Boards of …

[PDF][PDF] 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism …

B Solnica, G Sygitowicz, D Sitkiewicz… - Archives of Medical …, 2020 - termedia.pl
The lipid profile, which is routinely done to assess a cardiovascular risk, involves the
measurement/calculation of serum/plasma levels of total cholesterol (TC), high-density …

[HTML][HTML] 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

M Banach, S Surma, PP Toth - Archives of Medical Science: AMS, 2023 - ncbi.nlm.nih.gov
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias

MT Cooney, E Bruckert, A Cordero, A Corsini… - European heart …, 2016 - iris.unime.it
The content of these European Society of Cardiology (ESC) and European Atherosclerosis
Society Guidelines has been published for personal and educational use only. No …

National lipid association annual summary of clinical lipidology 2016

HE Bays, PH Jones, CE Orringer, WV Brown… - Journal of clinical …, 2016 - Elsevier
Abstract The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a
yearly updated summary of principles important to the patient-centered evaluation …

[HTML][HTML] Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study

M Vrablik, B Seifert, A Parkhomenko, M Banach… - Atherosclerosis, 2021 - Elsevier
Background and aims Central and Eastern Europe (CEE) is a largely understudied region,
despite having the highest cardiovascular disease mortality in Europe. This analysis aimed …

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and …

Ž Reiner, AL Catapano, G De Backer… - European heart …, 2011 - academic.oup.com
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

M Banach, S Surma, Z Reiner, N Katsiki… - Cardiovascular …, 2022 - Springer
Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled
worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol …